CARGO Therapeutics (NASDAQ:CRGX) Trading Down 3.7% – Should You Sell?

CARGO Therapeutics, Inc. (NASDAQ:CRGX)’s stock price traded down 3.7% during mid-day trading on Tuesday . The company traded as low as $13.97 and last traded at $14.17. 18,827 shares were traded during mid-day trading, a decline of 93% from the average session volume of 258,938 shares. The stock had previously closed at $14.72.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Chardan Capital reissued a “buy” rating and set a $28.00 price target on shares of CARGO Therapeutics in a research report on Wednesday, November 13th. William Blair assumed coverage on CARGO Therapeutics in a report on Tuesday, November 26th. They issued an “outperform” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $33.00 target price on shares of CARGO Therapeutics in a report on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, CARGO Therapeutics currently has an average rating of “Buy” and a consensus price target of $31.80.

CARGO Therapeutics Price Performance

The company’s 50-day moving average price is $18.40 and its two-hundred day moving average price is $17.91. The company has a market capitalization of $666.49 million and a P/E ratio of -3.40.

CARGO Therapeutics (NASDAQ:CRGX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.26. On average, analysts anticipate that CARGO Therapeutics, Inc. will post -3.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in CARGO Therapeutics by 11.5% during the second quarter. Bank of New York Mellon Corp now owns 69,171 shares of the company’s stock worth $1,136,000 after acquiring an additional 7,146 shares during the period. Rhumbline Advisers increased its holdings in shares of CARGO Therapeutics by 14.0% during the second quarter. Rhumbline Advisers now owns 30,639 shares of the company’s stock worth $503,000 after purchasing an additional 3,765 shares during the period. TD Asset Management Inc raised its position in shares of CARGO Therapeutics by 78.7% in the second quarter. TD Asset Management Inc now owns 289,352 shares of the company’s stock valued at $4,751,000 after buying an additional 127,418 shares in the last quarter. Cowen AND Company LLC boosted its stake in shares of CARGO Therapeutics by 121.7% in the second quarter. Cowen AND Company LLC now owns 554,305 shares of the company’s stock valued at $9,102,000 after buying an additional 304,305 shares during the period. Finally, Yu Fan bought a new position in CARGO Therapeutics during the 2nd quarter worth $14,975,000. Institutional investors own 93.16% of the company’s stock.

CARGO Therapeutics Company Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.